Other Event

Other Event

Other Adverse Events are non-serious adverse events that exceed a specific frequency threshold (typically 5% within any study arm). These events are reported to provide comprehensive safety information about all noteworthy adverse occurrences during clinical trials. Each other event is categorized by term, organ system, assessment type, and source vocabulary for standardized reporting.

Other Event path is as follows:

Study -> Results Section -> Adverse Events Module -> Other Event

Study -> Results Section -> Adverse Events Module -> Other Event -> Other Event Stats

Other Event


Ignite Creation Date: 2025-12-24 @ 10:12 PM
Ignite Modification Date: 2025-12-25 @ 7:48 PM
NCT ID: NCT02752035
Term: Vertigo
Organ System: Ear and labyrinth disorders
Assessment Type: SYSTEMATIC_ASSESSMENT
Source Vocabulary: MedDRA v23
Notes: None
Study: NCT02752035
Study Brief: A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
Other Event Stats (If Any):

Other Event Stats

Group ID # Events # Affected # At Risk View
EG000 2 2 15 View
EG001 1 1 88 View
EG002 0 0 54 View
EG003 1 1 22 View